BioXcel Therapeutics Announces Topline Results From Part 1 Of Pivotal SERENITY III Trial Of BXCL501 For At-Home Use In Acute Treatment Of Agitation In Bipolar Disorders Or Schizophrenia; Says 'Greater than 50% PEC response rate attained'
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics announced topline results from Part 1 of the pivotal SERENITY III trial of BXCL501 for at-home use in acute treatment of agitation in bipolar disorders or schizophrenia, achieving a greater than 50% PEC response rate.
May 25, 2023 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioXcel Therapeutics' BXCL501 achieves over 50% PEC response rate in Part 1 of SERENITY III trial for treating agitation in bipolar disorders and schizophrenia.
The positive topline results from the SERENITY III trial indicate that BXCL501 has potential in treating agitation in bipolar disorders and schizophrenia. This could lead to increased investor interest and a potential rise in BioXcel Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100